Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | GSK3A | P49840 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL236431 | 0.64 | TSHR (0.56) | GAAMEN1KMT2ATSHRSMN1; SMN2 | |
| SCHEMBL27394301 | 0.63 | TSHR (0.37) | GAAMEN1KMT2ATSHRSMN1; SMN2 | |
| SCHEMBL10729580 | 0.62 | L3MBTL1 (0.33) | GAAMEN1KMT2ATSHRSMN1; SMN2 | |
| SCHEMBL27308445 | 0.61 | TSHR (0.35) | MEN1KMT2ATSHRSMN1; SMN2HTT | |
| SCHEMBL4600179 | 0.61 | TSHR (0.52) | GAAMEN1KMT2ATSHRSMN1; SMN2 | |
| SCHEMBL5030065 | 0.60 | — | — | |
| Ethylene Glycol SCHEMBL27986613 | 0.60 | TSHR (0.50) | GAAMEN1KMT2ATSHRSMN1; SMN2 | |
| SCHEMBL7094711 | 0.58 | TSHR (0.35) | GAAMEN1KMT2ATSHRSMN1; SMN2 | |
| SCHEMBL27287079 | 0.58 | TSHR (0.36) | MEN1KMT2ATSHRSMN1; SMN2HTT | |
| SCHEMBL13299992 | 0.56 | ALDH1A1 (0.39) | MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221082-A1 | Ligands of Integrin Receptors | ABBOTT GMBH & CO. KG (DE) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221082-A1 | Ligands of Integrin Receptors | ITGB3, ITGAV, ITGA2B | GAA 3246/4885MEN1 4463/4885KMT2A 4698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.